• 1

    LaszloJ. Emesis as limiting toxicity in cancer chemotherapy. In: LaszloJ ed. Antiemetics and Cancer Chemotherapy. Baltimore, MD: Williams & Wilkins; 1983:15.

    • Search Google Scholar
    • Export Citation
  • 2

    IngleRJBurishTGWallstonKA. Conditionability of cancer chemotherapy patients. Oncol Nurs Forum1984;11:97102.

  • 3

    MitchellEP. Gastrointestinal toxicity of chemotherapeutic agents. Semin Oncol1992;19:566579.

  • 4

    RichardsonJLMarksGLevineA. The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol1988;6:17461752.

    • Search Google Scholar
    • Export Citation
  • 5

    HerrstedtJ. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol2008;5:3243.

  • 6

    HeskethPJGrunbergSMHerrstedtJ. Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer2006;14:354360.

    • Search Google Scholar
    • Export Citation
  • 7

    HeskethPJKrisMGGrunbergSM. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol1997;15:103109.

  • 8

    RoilaFHerrstedtJAaproM. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol2010;21(Suppl 5):v232243.

    • Search Google Scholar
    • Export Citation
  • 9

    GrunbergSMWarrDGrallaRJ. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-state of the art. Support Care Cancer2011;19(Suppl 1):S4347.

    • Search Google Scholar
    • Export Citation
  • 10

    RoscoeJAMorrowGRColagiuriB. Insight in the prediction of chemotherapy-induced nausea. Support Care Cancer2010;18:869876.

  • 11

    CraigJBPowellBL. The management of nausea and vomiting in clinical oncology. Am J Med Sci1987;293:3444.

  • 12

    BorisonHLWangSC. Physiology and pharmacology of vomiting. Pharmacol Rev1953;5:193230.

  • 13

    SeigelLJLongoDL. The control of chemotherapy-induced emesis. Ann Intern Med1981;95:352359.

  • 14

    DoddsLJ. The control of cancer chemotherapy-induced nausea and vomiting. J Clin Hosp Pharm1985;10:143166.

  • 15

    AaproMS. Palonosetron as an anti-emetic and anti-nausea agent in oncology. Ther Clin Risk Manag2007;3:10091020.

  • 16

    GrunbergSMDeusonRRMavrosP. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer2004;100:22612268.

  • 17

    HickokJTRoscoeJAMorrowGR. 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol2005;6:765772.

    • Search Google Scholar
    • Export Citation
  • 18

    KrisMGGrallaRJClarkRA. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol1985;3:13791384.

    • Search Google Scholar
    • Export Citation
  • 19

    RoilaFBoschettiETonatoM. Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Clin Oncol1991;14:238242.

    • Search Google Scholar
    • Export Citation
  • 20

    MoherDArthurAZPaterJL. Anticipatory nausea and/or vomiting. Cancer Treat Rev1984;11:257264.

  • 21

    JacobsenPBReddWH. The development and management of chemotherapy-related anticipatory nausea and vomiting. Cancer Invest1988;6:329336.

    • Search Google Scholar
    • Export Citation
  • 22

    MorrowGR. Clinical characteristics associated with the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment. J Clin Oncol1984;2:11701176.

    • Search Google Scholar
    • Export Citation
  • 23

    RoilaFHeskethPJHerrstedtJ. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol2006;17:2028.

    • Search Google Scholar
    • Export Citation
  • 24

    FeyerPCMaranzanoEMolassiotisA. Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009. Support Care Cancer2011;19(Suppl 1):S514.

    • Search Google Scholar
    • Export Citation
  • 25

    HardingRYoungRAnnoG. Radiotherapy-induced emesis. In: AndrewsPSangerG eds. Emesis in Anti-Cancer Therapy. London, England: Chapman & Hall Medical; 1993:163178.

    • Search Google Scholar
    • Export Citation
  • 26

    KrisMGHeskethPJSomerfieldMR. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol2006;24:29322947.

    • Search Google Scholar
    • Export Citation
  • 27

    LaszloJ. Treatment of nausea and vomiting caused by cancer chemotherapy. Cancer Treat Rev1982;9(Suppl B):39.

  • 28

    StrumSBMcDermedJEPileggiJ. Intravenous metoclopramide: prevention of chemotherapy-induced nausea and vomiting. A preliminary evaluation. Cancer1984;53:14321439.

    • Search Google Scholar
    • Export Citation
  • 29

    LindleyCMBernardSFieldsSM. Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J Clin Oncol1989;7:11421149.

    • Search Google Scholar
    • Export Citation
  • 30

    AaproM. Methodological issues in antiemetic studies. Invest New Drugs1993;11:243253.

  • 31

    GrunbergSMOsobaDHeskethPJ. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity: an update. Support Care Cancer2005;13:8084.

    • Search Google Scholar
    • Export Citation
  • 32

    KoellerJMAaproMSGrallaRJ. Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer2002;10:519522.

  • 33

    HeskethPJGandaraDR. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst1991;83:613620.

  • 34

    AndrewsPLBhandariPDaveyPT. Are all 5-HT3 receptor antagonists the same?Eur J Cancer1992;28A(Suppl 1):26.

  • 35

    GrunbergSMKoellerJM. Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis. Expert Opin Pharmacother2003;4:22972303.

    • Search Google Scholar
    • Export Citation
  • 36

    GrunbergSMStevensonLLRussellCAMcDermedJE. Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol1989;7:11371141.

    • Search Google Scholar
    • Export Citation
  • 37

    ChevallierB. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group. Eur J Cancer1990;26(Suppl 1):S3336.

    • Search Google Scholar
    • Export Citation
  • 38

    CupissolDRSerrouBCaubelM. The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis. Eur J Cancer1990;26(Suppl 1):S2327.

    • Search Google Scholar
    • Export Citation
  • 39

    De MulderPHSeynaeveCVermorkenJB. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. Ann Intern Med1990;113:834840.

    • Search Google Scholar
    • Export Citation
  • 40

    MartyM. A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. The Granisetron Study Group. Eur J Cancer1990;26(Suppl 1):S2832.

    • Search Google Scholar
    • Export Citation
  • 41

    MartyMPouillartPSchollS. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med1990;322:816821.

    • Search Google Scholar
    • Export Citation
  • 42

    SoukopM. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group. Eur J Cancer1990;26(Suppl 1):S1519.

    • Search Google Scholar
    • Export Citation
  • 43

    RoilaFTonatoMCognettiF. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol1991;9:675678.

    • Search Google Scholar
    • Export Citation
  • 44

    FraschiniG. Antiemetic activity of ondansetron in cancer patients receiving non-cisplatin chemotherapy. Semin Oncol1992;19:4147.

  • 45

    KamanabrouD. Intravenous granisetron: establishing the optimal dose. The Granisetron Study Group. Eur J Cancer1992;28A(Suppl 1):611.

    • Search Google Scholar
    • Export Citation
  • 46

    SledgeGWEinhornLNagyCHouseK. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer1992;70:25242528.

    • Search Google Scholar
    • Export Citation
  • 47

    ChevallierB. The control of acute cisplatin-induced emesis: a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. Granisetron Study Group. Br J Cancer1993;68:176180.

    • Search Google Scholar
    • Export Citation
  • 48

    NavariRMKaplanHGGrallaRJ. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol1994;12:22042210.

    • Search Google Scholar
    • Export Citation
  • 49

    RiviereA. Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. The Granisetron Study Group. Br J Cancer1994;69:967971.

    • Search Google Scholar
    • Export Citation
  • 50

    RojasCThomasAGAltJ. Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol2010;626:193199.

    • Search Google Scholar
    • Export Citation
  • 51

    AaproMSGrunbergSMManikhasGM. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol2006;17:14411449.

    • Search Google Scholar
    • Export Citation
  • 52

    EisenbergPFigueroa-VadilloJZamoraR. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer2003;98:24732482.

    • Search Google Scholar
    • Export Citation
  • 53

    GrallaRLichinitserMVan Der VegtS. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol2003;14:15701577.

    • Search Google Scholar
    • Export Citation
  • 54

    SaitoMAogiKSekineI. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol2009;10:115124.

    • Search Google Scholar
    • Export Citation
  • 55

    YangLPScottLJ. Palonosetron: in the prevention of nausea and vomiting. Drugs2009;69:22572278.

  • 56

    FDA Drug Safety Communication: Abnormal heart rythms associated with use of Anzemet (dolasetron mesylate). FDA Web site. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm237081.htm. Accessed June 6 2011.

    • Search Google Scholar
    • Export Citation
  • 57

    Sancuso (granisetron transdermal system) [package insert]. Bedminster, NJ: ProStrakan Inc.; 2008. Available at: http://www.sancuso.com/forms/SANCUSO-Full_PI.pdf. Accessed June 6 2011.

    • Search Google Scholar
    • Export Citation
  • 58

    BocciaRVGordanLNClarkG. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer2011;19:16091617.

    • Search Google Scholar
    • Export Citation
  • 59

    HowellJSmeetsJDrenthHJGillD. Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting. J Oncol Pharm Pract2009;15:223231.

    • Search Google Scholar
    • Export Citation
  • 60

    BonneterreJHecquetB. Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy. A cross-over study. Bull Cancer1995;82:10381043.

    • Search Google Scholar
    • Export Citation
  • 61

    JantunenITMuhonenTTKatajaVV. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy: a randomised study. Eur J Cancer1993;29A:16691672.

    • Search Google Scholar
    • Export Citation
  • 62

    MartoniAAngelelliBGuaraldiM. An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens. Eur J Cancer1996;32A:8285.

    • Search Google Scholar
    • Export Citation
  • 63

    GebbiaVCannataGTestaA. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. Cancer1994;74:19451952.

    • Search Google Scholar
    • Export Citation
  • 64

    MantovaniGMaccioABianchiA. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Cancer1996;77:941948.

    • Search Google Scholar
    • Export Citation
  • 65

    NobleABremerKGoedhalsL. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. The Granisetron Study Group. Eur J Cancer1994;30A:10831088.

    • Search Google Scholar
    • Export Citation
  • 66

    RuffPPaskaWGoedhalsL. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group. Oncology1994;51:113118.

    • Search Google Scholar
    • Export Citation
  • 67

    Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group of Antiemetic Research. Ann Oncol1995;6:805810.

    • Search Google Scholar
    • Export Citation
  • 68

    NavariRGandaraDHeskethP. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. J Clin Oncol1995;13:12421248.

    • Search Google Scholar
    • Export Citation
  • 69

    StewartAMcQuadeBCronjeJD. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Emesis Study Group for Ondansetron and Granisetron in Breast Cancer Patients. Oncology1995;52:202210.

    • Search Google Scholar
    • Export Citation
  • 70

    AudhuyBCappelaerePMartinM. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer1996;32A:807813.

    • Search Google Scholar
    • Export Citation
  • 71

    FauserAADuclosBChemaissaniA. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group. Eur J Cancer1996;32A:15231529.

    • Search Google Scholar
    • Export Citation
  • 72

    HeskethPNavariRGroteT. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. J Clin Oncol1996;14:22422249.

    • Search Google Scholar
    • Export Citation
  • 73

    LoftersWSPaterJLZeeB. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol1997;15:29662973.

    • Search Google Scholar
    • Export Citation
  • 74

    JordanKHinkeAGrotheyA. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer2007;15:10231033.

    • Search Google Scholar
    • Export Citation
  • 75

    BillioAMorelloEClarkeMJ. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults. Cochrane Database Syst Rev2010:CD006272.

    • Search Google Scholar
    • Export Citation
  • 76

    BotrelTEClarkOAClarkL. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT(3)R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer2011;19:823832.

    • Search Google Scholar
    • Export Citation
  • 77

    AaproMFabiANoleF. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol2010;21:10831088.

    • Search Google Scholar
    • Export Citation
  • 78

    HuangJQZhengGFDeusonR. Do 5-hydroxytryptamine3 receptor antagonists (5-HT3) improve the antiemetic effect of dexamethasone for preventing delayed chemotherapy-induced nausea and vomiting (CINV)? A meta-analysis of randomized controlled trials [abstract]. J Clin Oncol2004;22(Suppl 14):Abstract 6037.

    • Search Google Scholar
    • Export Citation
  • 79

    GrallaRJde WitRHerrstedtJ. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two phase III randomized clinical trials. Cancer2005;104:864868.

    • Search Google Scholar
    • Export Citation
  • 80

    HeskethPJGrunbergSMGrallaRJ. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin: the Aprepitant Protocol 052 Study Group. J Clin Oncol2003;21:41124119.

    • Search Google Scholar
    • Export Citation
  • 81

    Poli-BigelliSRodrigues-PereiraJCaridesAD. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer2003;97:30903098.

    • Search Google Scholar
    • Export Citation
  • 82

    Tremont-LukatsIWGonzalez-BarboteoJBrueraEBresciaFJ. Meta-analysis of neurokinin-1 receptor antagonists (NK-1 RA) for chemotherapy-induced nausea and vomiting (CINV) [abstract]. J Clin Oncol2004;22(Suppl 14):Abstract 8047.

    • Search Google Scholar
    • Export Citation
  • 83

    WarrDGHeskethPJGrallaRJ. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol2005;23:28222830.

    • Search Google Scholar
    • Export Citation
  • 84

    GroteTHajdenbergJCartmellA. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol2006;4:403408.

    • Search Google Scholar
    • Export Citation
  • 85

    GrunbergSMDuganMMussH. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer2009;17:589594.

    • Search Google Scholar
    • Export Citation
  • 86

    EMEND (aprepitant) capsules [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2011. Available at: http://www.merck.com/product/usa/pi_circulars/e/emend/emend_pi.pdf. Accessed June 6 2011.

    • Search Google Scholar
    • Export Citation
  • 87

    ChawlaSPGrunbergSMGrallaRJ. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer2003;97:22902300.

    • Search Google Scholar
    • Export Citation
  • 88

    EMEND (fosaprepitant dimeglumine) [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2011. Available at: http://www.merck.com/product/usa/pi_circulars/e/emend_iv/emend_iv_pi.pdf. Accessed June 6 2011.

    • Search Google Scholar
    • Export Citation
  • 89

    MarburyTCNgoPLShadleCR. Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects. J Clin Pharmacol2011;51:17121720.

    • Search Google Scholar
    • Export Citation
  • 90

    LasseterKCGambaleJJinB. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol2007;47:834840.

    • Search Google Scholar
    • Export Citation
  • 91

    GrunbergSChuaDMaruA. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol—EASE. J Clin Oncol2011;29:14951501.

    • Search Google Scholar
    • Export Citation
  • 92

    ShadleCRLeeYMajumdarAK. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol2004;44:215223.

    • Search Google Scholar
    • Export Citation
  • 93

    WamplerG. The pharmacology and clinical effectiveness of phenothiazines and related drugs for managing chemotherapy-induced emesis. Drugs1983;25(Suppl 1):3551.

    • Search Google Scholar
    • Export Citation
  • 94

    GrallaRJItriLMPiskoSE. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med1981;305:905909.

    • Search Google Scholar
    • Export Citation
  • 95

    GrallaRJTysonLBBordinLA. Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol. Cancer Treat Rep1984;68:163172.

    • Search Google Scholar
    • Export Citation
  • 96

    BakowskiMT. Advances in anti-emetic therapy. Cancer Treat Rev1984;11:237256.

  • 97

    GrossmanBLessinLSCohenP. Droperidol prevents nausea and vomiting from cis-platinum. N Engl J Med1979;301:47.

  • 98

    AaproMSAlbertsDS. High-dose dexamethasone for prevention of cis-platin-induced vomiting. Cancer Chemother Pharmacol1981;7:1114.

  • 99

    AaproMSPleziaPMAlbertsDS. Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide. J Clin Oncol1984;2:466471.

    • Search Google Scholar
    • Export Citation
  • 100

    CassilethPALuskEJTorriS. Antiemetic efficacy of dexamethasone therapy in patients receiving cancer chemotherapy. Arch Intern Med1983;143:13471349.

    • Search Google Scholar
    • Export Citation
  • 101

    KrisMGGrallaRJClarkRA. Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone. Cancer Treat Rep1985;69:12571262.

    • Search Google Scholar
    • Export Citation
  • 102

    KrisMGGrallaRJClarkRA. Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial. Cancer1987;60:28162822.

    • Search Google Scholar
    • Export Citation
  • 103

    HermanTSEinhornLHJonesSE. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med1979;300:12951297.

    • Search Google Scholar
    • Export Citation
  • 104

    SteeleNGrallaRJBraunDWYoungCW. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep1980;64:219224.

    • Search Google Scholar
    • Export Citation
  • 105

    NavariRMEinhornLHPassikSD. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer2005;13:529534.

    • Search Google Scholar
    • Export Citation
  • 106

    SrivastavaMBrito-DellanNDavisMP. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manage2003;25:578582.

    • Search Google Scholar
    • Export Citation
  • 107

    PassikSDNavariRMJungSH. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest2004;22:383388.

    • Search Google Scholar
    • Export Citation
  • 108

    PassikSDKirshKLTheobaldDE. A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manage2003;25:485488.

    • Search Google Scholar
    • Export Citation
  • 109

    PassikSDLundbergJKirshKL. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage2002;23:526532.

    • Search Google Scholar
    • Export Citation
  • 110

    ZYPREXA (olanzapine) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2010. Available at: http://pi.lilly.com/us/zyprexa-pi.pdf. Accessed June 6 2011.

    • Search Google Scholar
    • Export Citation
  • 111

    MoritaTTeiYShishidoHInoueS. Olanzapine-induced delirium in a terminally ill cancer patient. J Pain Symptom Manage2004;28:102103.

  • 112

    Eating hints: before during and after cancer treatment. 2009. National Cancer Institute Web site. Available at: http://www.cancer.gov/cancertopics/coping/eatinghints/page1. Accessed June 6 2011.

    • Search Google Scholar
    • Export Citation
  • 113

    GelingOEichlerHG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol2005;23:12891294.

    • Search Google Scholar
    • Export Citation
  • 114

    FDA requires boxed warning and risk mitigation strategy for metoclopramide-containing drugs. FDA Web site. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm149533.htm. Accessed June 6 2011.

    • Search Google Scholar
    • Export Citation
  • 115

    PasrichaPJPehlivanovNSugumarAJankovicJ. Drug insight: from disturbed motility to disordered movement—a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol2006;3:138148.

    • Search Google Scholar
    • Export Citation
  • 116

    KawanishiCOnishiHKatoD. Unexpectedly high prevalence of akathisia in cancer patients. Palliat Support Care2007;5:351354.

  • 117

    PatanwalaAEAminiRHaysDPRosenP. Antiemetic therapy for nausea and vomiting in the emergency department. J Emerg Med2010;39:330336.

  • 118

    VinsonDR. Diphenhydramine in the treatment of akathisia induced by prochlorperazine. J Emerg Med2004;26:265270.

  • 119

    RoilaFWarrDClark-SnowRA. Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer2005;13:104108.

  • 120

    MASCC/ESMO Antiemetic Guideline 2011. Available at: http://data.memberclicks.com/site/mascc/MASCC_Guidelines_English_2011.pdf. Accessed June 6 2011.

    • Search Google Scholar
    • Export Citation
  • 121

    GrunbergSClark-SnowRAKoellerJ. Chemotherapy-induced nausea and vomiting: contemporary approaches to optimal management: proceedings from a symposium at the 2008 Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting. Support Care Cancerin press.

    • Search Google Scholar
    • Export Citation
  • 122

    OrmrodDGoaKL. Intranasal metoclopramide. Drugs1999;58:315322.

  • 123

    UrbaS. Radiation-induced nausea and vomiting. J Natl Compr Canc Netw2007;5:6065.

  • 124

    MaranzanoEFeyerPMolassiotisA. Evidence-based recommendations for the use of antiemetics in radiotherapy. Radiother Oncol2005;76:227233.

    • Search Google Scholar
    • Export Citation
  • 125

    SalvoNDobleBKhanL. Prophylaxis of radiation-induced nausea and vomiting using 5-hydroxytryptamine-3 serotonin receptor antagonists: a systematic review of randomized trials. Int J Radiat Oncol Biol Phys2012;82:408417.

    • Search Google Scholar
    • Export Citation
  • 126

    FranzenLNymanJHagbergH. A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy. Ann Oncol1996;7:587592.

    • Search Google Scholar
    • Export Citation
  • 127

    WongRKPaulNDingK. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). J Clin Oncol2006;24:34583464.

    • Search Google Scholar
    • Export Citation
  • 128

    LancianoRShermanDMMichalskiJ. The efficacy and safety of once-daily Kytril (granisetron hydrochloride) tablets in the prophylaxis of nausea and emesis following fractionated upper abdominal radiotherapy. Cancer Invest2001;19:763772.

    • Search Google Scholar
    • Export Citation
  • 129

    SpitzerTRFriedmanCJBushnellW. Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation. Bone Marrow Transplant2000;26:203210.

    • Search Google Scholar
    • Export Citation
  • 130

    RoscoeJAMorrowGRAaproMS. Anticipatory nausea and vomiting. Support Care Cancer2011;19:15331538.

  • 131

    AaproMSMolassiotisAOlverI. Anticipatory nausea and vomiting. Support Care Cancer2005;13:117121.

  • 132

    EzzoJVickersARichardsonMA. Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting. J Clin Oncol2005;23:71887198.

    • Search Google Scholar
    • Export Citation
  • 133

    MorrowGRMorrellC. Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med1982;307:14761480.

    • Search Google Scholar
    • Export Citation
  • 134

    ReddWHAndrykowskiMA. Behavioral intervention in cancer treatment: controlling aversion reactions to chemotherapy. J Consult Clin Psychol1982;50:10181029.

    • Search Google Scholar
    • Export Citation
  • 135

    EzzoJStreitbergerKSchneiderA. Cochrane systematic reviews examine P6 acupuncture-point stimulation for nausea and vomiting. J Altern Complement Med2006;12:489495.

    • Search Google Scholar
    • Export Citation
  • 136

    Figueroa-MoseleyCJean-PierrePRoscoeJA. Behavioral interventions in treating anticipatory nausea and vomiting. J Natl Compr Canc Netw2007;5:4450.

    • Search Google Scholar
    • Export Citation
  • 137

    MolassiotisAYungHPYamBM. The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients: a randomised controlled trial. Support Care Cancer2002;10:237246.

    • Search Google Scholar
    • Export Citation
  • 138

    RazaviDDelvauxNFarvacquesC. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. J Clin Oncol1993;11:13841390.

    • Search Google Scholar
    • Export Citation
  • 139

    MalikIAKhanWAQazilbashM. Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol1995;18:170175.

    • Search Google Scholar
    • Export Citation
  • 140

    XANAX [package insert]. New York, NY: Pfizer Inc.; 2011. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=547. Accessed June 6 2011.

    • Search Google Scholar
    • Export Citation
  • 141

    de WitRHerrstedtJRapoportB. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer2004;40:403410.

    • Search Google Scholar
    • Export Citation
  • 142

    EllebaekEHerrstedtJ. Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy. Curr Opin Support Palliat Care2008;2:2834.

    • Search Google Scholar
    • Export Citation
  • 143

    EinhornLHRapoportBKoellerJ. Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer2005;13:112116.

    • Search Google Scholar
    • Export Citation
  • 144

    NavariRM. Prevention of emesis from multiple-day and high-dose chemotherapy regimens. J Natl Compr Canc Netw2007;5:5159.

  • 145

    HerrstedtJSigsgaardTCNielsenHA. Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy. Support Care Cancer2007;15:417426.

    • Search Google Scholar
    • Export Citation
  • 146

    MierJWVachinoGKlempnerMS. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood1990;76:19331940.

    • Search Google Scholar
    • Export Citation
  • 147

    MussoMScaloneRBonannoV. Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. Support Care Cancer2009;17:205209.

    • Search Google Scholar
    • Export Citation
  • 148

    CelioLDenaroACanovaS. Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting. Tumori2008;94:447452.

    • Search Google Scholar
    • Export Citation
  • 149

    EisenbergPMacKintoshFRRitchP. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol2004;15:330337.

    • Search Google Scholar
    • Export Citation
  • 150

    EinhornLHBramesMJDreicerR. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer2007;15:12931300.

    • Search Google Scholar
    • Export Citation
  • 151

    GiraltSAManganKFMaziarzRT. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Ann Oncol2011;22:939946.

    • Search Google Scholar
    • Export Citation
  • 152

    JordanKKinitzIVoigtW. Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer2009;45:11841187.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 443 373 20
PDF Downloads 68 59 6
EPUB Downloads 0 0 0